Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design
Designing optimal (neo)adjuvant therapy is a crucial aspect of the treatment of non-small-cell lung carcinoma (NSCLC). Standard methods of chemotherapy, radiotherapy, and immunotherapy represent effective strategies for treatment. However, in some cases with high metastatic activity and high levels...
Enregistré dans:
Auteurs principaux: | Zdeněk Kejík, Robert Kaplánek, Petr Dytrych, Michal Masařík, Kateřina Veselá, Nikita Abramenko, David Hoskovec, Martina Vašáková, Jarmila Králová, Pavel Martásek, Milan Jakubek |
---|---|
Format: | article |
Langue: | EN |
Publié: |
MDPI AG
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/a9212fe2fd9443cd854b6088bd96b44c |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Cell-Free DNA Variant Sequencing Using Plasma and AR-V7 Testing of Circulating Tumor Cells in Prostate Cancer Patients
par: Verena Lieb, et autres
Publié: (2021) -
Polymer nanofiber-based microchips for EGFR mutation analysis of circulating tumor cells in lung adenocarcinoma
par: Jiang WT, et autres
Publié: (2018) -
Multifunctional Gold Nano-Cytosensor With Quick Capture, Electrochemical Detection, and Non-Invasive Release of Circulating Tumor Cells for Early Cancer Treatment
par: Rui Zhang, et autres
Publié: (2021) -
Liquid biopsy for cancer management: a revolutionary but still limited new tool for precision medicine
par: Arechederra María, et autres
Publié: (2020) -
Preparation and Characterization of Highly Water Soluble Curcumin – Dextrose Cocrystal
par: Katherine Kho, et autres
Publié: (2018)